GH Research PLC — Investor Relations & Filings
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing therapies for psychiatric and neurological disorders. The company's pipeline is centered on its novel and proprietary mebufotenin (5-MeO-DMT) product candidates. Its lead program, GH001, is an inhaled formulation of mebufotenin being developed for treatment-resistant depression (TRD). Other clinical programs are exploring treatments for bipolar II disorder with a depressive episode and postpartum depression. The company aims to deliver therapies with faster onset of action, durable effects, and improved remission rates. GH Research owns a growing intellectual property portfolio related to mebufotenin's therapeutic applications, formulations, and manufacturing methods.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-21 | English | |
| 6-K | 2026-05-14 | English | |
| 424B5 | 2026-05-14 | English | |
| 6-K | 2026-05-14 | English | |
| 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | |
| 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46729565 | 6-K | 2026-05-21 | English | ||
| 46257322 | 6-K | 2026-05-14 | English | ||
| 46028749 | 424B5 | 2026-05-14 | English | ||
| 45974635 | 6-K | 2026-05-14 | English | ||
| 45767036 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | ||
| 45554240 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-05-13 | English | ||
| 38566840 | 424B5 - GH Research PLC (0001855129) (Filer) | 2026-04-29 | English | ||
| 33041100 | 6-K - GH Research PLC (0001855129) (Filer) | 2026-03-25 | English | ||
| 32083527 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13427655 | 6-K | 2026-01-22 | English | ||
| 13427654 | 6-K | 2026-01-15 | English | ||
| 13427656 | 6-K | 2026-01-13 | English | ||
| 13427657 | 6-K | 2026-01-08 | English | ||
| 13427658 | 6-K | 2026-01-05 | English | ||
| 13427659 | 6-K | 2026-01-02 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for GH Research PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
|
Caliway
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
GH Research PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32311/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32311 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32311 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32311 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32311}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GH Research PLC (id: 32311)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.